ARS Pharmaceuticals, Inc. Earnings Per Share (Basic)
ARS Pharmaceuticals, Inc. (SPRY) reported Earnings Per Share (Basic) of -$0.63 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.63.
- ARS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.61.
- ARS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.42, a 181.40% decline year-over-year.
- ARS Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.52.
- ARS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$1.74, a 2275.00% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was $0.08.
- ARS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$0.57.
- ARS Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$0.87.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.63 10-Q · filed 2026-08-13 | -$1.24 10-Q · filed 2026-08-13 | -$1.66 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2026-03-31 | -$0.61 10-Q · filed 2026-05-15 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$2.00 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2025-12-31 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.39 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.74 10-K · filed 2026-03-09 | ||
| 2025-09-30 | -$0.52 10-Q · filed 2025-11-10 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.32 10-Q · filed 2025-11-10 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2025-06-30 | -$0.46 10-Q · filed 2026-08-13 | -$0.80 10-Q · filed 2026-08-13 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2025-03-31 | -$0.35 10-Q · filed 2026-05-15 | $0.16 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$0.03 derived: net income ÷ weighted average shares · filed 2026-05-15 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-05-15 | ||
| 2024-12-31 | $0.51 derived: net income ÷ weighted average shares · filed 2026-04-29 | $0.32 derived: net income ÷ weighted average shares · filed 2026-04-29 | $0.19 derived: net income ÷ weighted average shares · filed 2026-04-29 | $0.08 10-K · filed 2026-03-09 | ||
| 2024-09-30 | -$0.20 10-Q · filed 2025-11-10 | -$0.33 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$0.43 10-Q · filed 2025-11-10 | -$0.51 derived: net income ÷ weighted average shares · filed 2025-11-10 | ||
| 2024-06-30 | -$0.13 10-Q · filed 2025-08-13 | -$0.24 10-Q · filed 2025-08-13 | -$0.31 derived: net income ÷ weighted average shares · filed 2025-08-13 | -$0.47 derived: net income ÷ weighted average shares · filed 2025-08-13 | ||
| 2024-03-31 | -$0.11 10-Q · filed 2025-05-14 | -$0.18 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$0.34 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$0.52 derived: net income ÷ weighted average shares · filed 2025-05-14 | ||
| 2023-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.23 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.41 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.57 10-K · filed 2025-03-20 | ||
| 2023-09-30 | -$0.16 10-Q · filed 2024-11-13 | -$0.34 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$0.50 10-Q · filed 2024-11-13 | -$0.70 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||
| 2023-06-30 | -$0.18 10-Q · filed 2024-08-06 | -$0.34 10-Q · filed 2024-08-06 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-08-06 | -$0.74 derived: net income ÷ weighted average shares · filed 2024-08-06 | ||
| 2023-03-31 | -$0.16 10-Q · filed 2024-05-09 | -$0.36 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$0.56 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-05-09 | ||
| 2022-12-31 | -$0.21 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$0.43 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$0.64 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$0.87 10-K · filed 2024-03-21 | ||
| 2022-09-30 | -$0.21 10-Q · filed 2023-11-09 | -$0.50 10-Q · filed 2022-11-02 | -$0.42 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.66 10-Q · filed 2023-11-09 | -$1.76 10-Q · filed 2022-11-02 | $1.00 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.21 10-Q · filed 2023-08-10 | -$0.45 10-Q · filed 2023-08-10 | $1.34 derived: net income ÷ weighted average shares · filed 2023-08-10 | $0.35 derived: net income ÷ weighted average shares · filed 2023-08-10 | ||
| 2022-03-31 | -$0.24 10-Q · filed 2023-05-15 | $1.87 derived: net income ÷ weighted average shares · filed 2023-05-15 | $0.62 derived: net income ÷ weighted average shares · filed 2023-05-15 | |||
| 2021-12-31 | $4.22 derived: net income ÷ weighted average shares · filed 2023-03-23 | $1.01 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$0.70 10-K · filed 2023-03-23 | |||
| 2021-09-30 | -$0.65 10-Q · filed 2022-11-02 | -$1.89 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |